Cell line · CVCL_0428
Papers295
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 295
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Pharmacokinetic Tuning Redirects β‐Lapachone From NQO1 Bioactivation to Vimentin‐Targeted Oxidation in Cancer | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| o-carborane encapsulated into polymeric micelles for proton boron capture therapy. | Cancer Nanotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SERPINB5 and MSLN for Pancreatic Cancer Therapy. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. | Chem Biodivers | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic Efficacy and Safety of Intraperitoneally Administered 211At-Labeled Gold Nanoparticles for Peritoneally Disseminated Malignancies. | Pharmaceutics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Type I interferons modulate autophagy to shape gemcitabine response in pancreatic cancer cells. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dual Targeting of FGFR4 and PI3K-mTOR Suppresses Tumor-Associated Phenotypes in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| HRAS promotes mutant NRAS-driven transformation with codon and allele specificity. | Sci Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. | Cancer Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MicroRNA-15a/16 regulate protein metabolism and are associated with clinical outcomes in pancreatic ductal adenocarcinoma. | Physiol Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pancreatic Cancer-Derived Small Extracellular Vesicles Remodel Hepatic Pre-Metastatic Niche via Hybrid Epithelial-Mesenchymal States. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERO1L induces macrophage infiltration to potentiate KrasG12D and inflammation-induced pancreatic tumorigenesis via oxidative protein folding of CCL2. | Cell Biosci | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0428/papers